滚动资讯
FierceBiotechBlackstone closes record $6.3B life sciences fundFierceBiotechAstellas axes early Sjögren’s trial in latest setback for autoimmune disease communityFierceBiotechJohnson & Johnson’s Impella pumps miss the mark in 2 major coronary studiesBioPharma DiveUnited rises on IPF data; Biogen scores positive lupus data and an approvalEndpoints News#ACC26: Merck touts comparator data for oral cholesterol drugEndpoints News#AAD26 roundup: Takeda, Alumis, Priovant and Incyte take the stageEndpoints NewsDrugmakers skeptical of new White House overtures on pricingEndpoints NewsSamsung Bio union workers threaten strike over pay, disclosure of employee dataEndpoints NewsPost-Hoc Live: Will MAHA vaccine policies be a political problem for Republicans?FierceBiotechViridian’s other rival to Amgen’s Tepezza scores phase 3 win, but investors need convincingFierceBiotechKevin Tang uses newfound control of Aurinia to finally take over KezarFierceBiotechBoston Scientific’s Watchman heart implant measures up to blood thinners in ACC trial
Endpoints News 2026年3月30日

Drugmakers skeptical of new White House overtures on pricing

Drugmakers skeptical of new White House overtures on pricing

原文
暂时没有全文，请查看原始来源。

目录

59 全部